{
    "clinical_study": {
        "@rank": "13432", 
        "arm_group": {
            "arm_group_label": "ME-344", 
            "arm_group_type": "Experimental", 
            "description": "ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability of ME-344 when given\n      in combination with Hycamtin\u00ae in patients with solid tumors"
        }, 
        "brief_title": "ME-344 Given in Combination With Hycamtin\u00ae in Patients With Solid Tumors", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic or cytologic confirmed locally advanced or metastatic small cell lung\n             cancer, ovarian cancer, or cervical cancer (Part 1); small cell lung cancer and\n             ovarian cancer (Part 2)\n\n          -  Patients with ovarian and small cell lung cancer must have failed initial therapy\n\n          -  Patients with carcinoma of the cervix must have advanced disease not amenable to\n             curative surgery and/or radiation therapy\n\n          -  Patients may not have received more than 4 prior regimens of therapy\n\n          -  Patients may not previously have received irinotecan, topotecan or other\n             topoisomerase I inhibitor\n\n          -  ECOG Performance status 0-1 (Appendix B)\n\n          -  A minimum life expectancy of 12 weeks\n\n          -  Adequate bone marrow, hepatic and renal function as evidenced by:\n\n               -  Absolute neutrophil count (ANC) > 1.5 x 109/L\n\n               -  Platelet count > 100 x 109/L\n\n               -  Hemoglobin > 9.0 g/dL\n\n               -  Serum bilirubin < 1.5 x ULN\n\n               -  AST/ALT (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x --ULN in\n                  the presence of liver metastases\n\n               -  Serum creatinine < 1.5 x ULN or creatinine clearance \u2265 60 mL/min as measured by\n                  institutional standards\n\n          -  At least 21 days must have elapsed prior to Day 1 Cycle 1, since any radiotherapy,\n             immunotherapy or following major surgery; any surgical incision should be completely\n             healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 since \"limited\n             palliative radiotherapy\", defined as a course of therapy encompassing <25% total bone\n             marrow volume and not exceeding 30 GY.\n\n        Exclusion Criteria:\n\n          -  Patients with tumor involvement of the Central Nervous System (CNS).  SCLC patients\n             with previously treated CNS lesions must have stable CNS disease for at least 4 weeks\n\n          -  Patients with uncontrolled infection or systemic disease\n\n          -  Patients with clinically significant cardiac disease not well controlled with\n             medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g.\n             angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months\n\n          -  Patients who have toxicity from last prior therapy that has not recovered to at least\n             Grade 1, with the exception of Grade 2 alopecia\n\n          -  Patients who have had any chemotherapy regimens, biologic, or targeted therapies\n             within the 2 weeks prior to Cycle 1 Day 1\n\n          -  Patients with any neuropathy > Grade 1\n\n          -  Patients with known hypersensitivity to any components of ME-344 or topotecan study\n             drug product\n\n          -  Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active,\n             previously treated or both)\n\n          -  Patients with a history of solid organ transplantation\n\n          -  Patients with any psychiatric disorder or social or geographic situation that would\n             preclude  study participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100007", 
            "org_study_id": "ME-344-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "ME-344", 
                "description": "Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.\nPatients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator.", 
                "intervention_name": "ME-344", 
                "intervention_type": "Drug", 
                "other_name": "open label"
            }, 
            {
                "arm_group_label": "ME-344", 
                "description": "Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.", 
                "intervention_name": "Topotecan", 
                "intervention_type": "Drug", 
                "other_name": "Hycamtin\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Topotecan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "solid tumors", 
            "relapsed", 
            "advanced", 
            "metastatic", 
            "small cell lung cancer", 
            "ovarian cancer", 
            "refractory"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "link": {
            "description": "Sponsor website", 
            "url": "http://www.meipharma.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "dmericle@azoph.com", 
                    "last_name": "David Mericle, RN", 
                    "phone": "480-860-5000"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Pinnacle Oncology Hematology"
                }, 
                "investigator": {
                    "last_name": "Michael Gordon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "haley.chiles@ucdenver.edu", 
                    "last_name": "Haley Chiles", 
                    "phone": "720-848-5097"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jennifer Diamond, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amy.hoyer@northwestern.edu", 
                    "last_name": "Amy Hoyer", 
                    "phone": "312-695-1341"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }, 
                "investigator": {
                    "last_name": "Melissa Johnson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "amy-sanmann@ouhsc.edu", 
                    "last_name": "Amy Sanmann", 
                    "phone": "405-271-8001", 
                    "phone_ext": "48633"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "University of Oklahoma"
                }, 
                "investigator": {
                    "last_name": "Katheleen Moore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "brisend@musc.edu", 
                    "last_name": "Alan Brisendine", 
                    "phone": "843-792-9007"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }, 
                "investigator": {
                    "last_name": "Carolyn Britten, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ASKSARAH@scresearch.net", 
                    "last_name": "Marla Schider, RN", 
                    "phone": "615-339-4214"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology, PLLC"
                }, 
                "investigator": {
                    "last_name": "Johanna Bendell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mollerup@u.washington.edu", 
                    "last_name": "Audrey Mesher", 
                    "phone": "206-288-2056"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "University of WA Seattle Cancer Care Alliance"
                }, 
                "investigator": {
                    "last_name": "Barbara Goff, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin\u00ae) in Patients With Solid Tumors", 
        "overall_contact": {
            "last_name": "Vanessa Esquibel", 
            "phone": "858-369-7174"
        }, 
        "overall_official": {
            "affiliation": "MEI Pharma, Inc.", 
            "last_name": "Wendy J Levin, MD, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be administered ME-344 10 mg/kg IV infusions in combination with topotecan 4 mg/m2 i.v. If dose-limiting toxicity is observed an additional patients may be treated with ME-344 at the 5 mg/kg dose level. Patients will be assessed by physical exam, vital signs, changes in ECOG status, hematology labs, clinical chemistry labs, urinalysis, and ECG", 
            "measure": "Combination of dosing ME-344 in combination with topotecan in patients with solid tumors", 
            "safety_issue": "Yes", 
            "time_frame": "One 28 day cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100007"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Peak Plasma Concentration (Cmax) and Area under the plasma concentration  versus time curve (AUC) of ME-344 in combination with topotecan", 
            "measure": "Characterize the pharmacokinetic profile of ME-344 in combination with topotecan", 
            "safety_issue": "Yes", 
            "time_frame": "Cycle 1 Day 1, at 0, .5, 1, 2, 4, 6 and 24 hours post-dose and Day 15 at 0 and end of infusion"
        }, 
        "source": "MEI Pharma, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "MEI Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}